Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 967Precursor Cell Lymphoblastic Leukemia-Lymphoma 585Leukemia, Lymphocytic, Chronic, B-Cell 555Leukemia 486Myelodysplastic Syndromes 375Lymphoma, Non-Hodgkin 347Lymphoma 297Lymphoma, Mantle-Cell 263Hematologic Neoplasms 260Lymphoma, Follicular 256Lymphoma, Large B-Cell, Diffuse 253Burkitt Lymphoma 232Lymphoma, B-Cell, Marginal Zone 227Recurrence 216Hodgkin Disease 182Multiple Myeloma 172Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 159Lymphoma, Large-Cell, Immunoblastic 158Leukemia, Myelomonocytic, Chronic 153Leukemia, Myelogenous, Chronic, BCR-ABL Positive 147Waldenstrom Macroglobulinemia 123Lymphoma, T-Cell, Cutaneous 116Neoplasms 112Lymphoma, Large-Cell, Anaplastic 111Blast Crisis 105Congenital Abnormalities 104Immunoblastic Lymphadenopathy 98Mycosis Fungoides 97Sezary Syndrome 96Myeloproliferative Disorders 92

Interventions

selinexor 1Panobinostat 1Daunorubicin 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Chromosome Aberrations × Other hematologic neoplasm × Clear all
NCT02403310 2022-10-03

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
21 enrolled
Other hematologic neoplasm

Chromosome Aberrations, Leukemia, Leukemia, Myeloid, Acute

NCT01242774 2020-12-19

Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

Novartis

Phase 1 Completed
46 enrolled
Other hematologic neoplasm

Chromosome Aberrations, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡